Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Nasalcrom new product bulletin

This article was originally published in The Tan Sheet

Executive Summary

Nasalcrom new product bulletin: American Pharmaceutical Association booklet advises pharmacists that "cromolyn sodium in oral, parenteral and inhaled forms has a wide margin of safety" and "the risk of toxicity from an overdose is extremely low"; however, "patients should be warned that cromolyn sodium can cause transient nasal stinging, sneezing, or both immediately after administration of the drug." These effects "rarely require discontinuation of therapy." Cromolyn sodium is "well tolerated and has few precautions" and "may be useful for patients who cannot take or tolerate antihistamines and decongestants because of concomitant medical conditions or adverse effects" or in patients whose symptoms are not controlled by these types of medications. The allergy prevention and treatment product was recently purchased from Rx-to-OTC switch sponsor McNeil Consumer Products by Pharmacia & Upjohn ("The Tan Sheet" June 9, p. 2)...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087176

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel